The effect of risedronate [risedronic acid] on bone turnover and bone mass in older men receiving neoadjuvant therapy for prostate cancer

Trial Profile

The effect of risedronate [risedronic acid] on bone turnover and bone mass in older men receiving neoadjuvant therapy for prostate cancer

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Oct 2016

At a glance

  • Drugs Risedronic acid (Primary)
  • Indications Bone resorption; Male osteoporosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Jul 2012 Actual patient number changed from 40 to 50 as reported ClinicalTrials.gov.
    • 07 Mar 2009 Trial phase, start and end dates, patient number, identifiers, sponsors and lead investigator and endpoints added from ClinicalTrials.gov.
    • 07 Mar 2009 Status changed from not stated to completed, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top